Details:
epicite® balance is made of biosynthetic cellulose, a hydropolymer for innovative medical device applications. The dressing enables superior wound cleansing effects and reactivates the healing of slow-healing wounds.
Lead Product(s): Cellulose
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Epicite® Balance
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: JeNaCell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2023
Details:
epicite® balance is made of biosynthetic cellulose, a hydropolymer for innovative medical device applications. The dressing enables superior wound cleansing effects and reactivates the healing of slow-healing wounds.
Lead Product(s): Cellulose
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Epicite® Balance
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: JeNaCell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
ATX-101 is a small product placed directly into the TKA surgical site in a simple, ‘place & go’ manner designed to add minimal extra complexity and time to the procedure.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: ATX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allay Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Voquezna Triple Pack
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phathom Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 24, 2022
Details:
Lipids, molecules that make up the building blocks of living cells, are critical to producing mRNA-based drugs. The mRNA is enclosed in a lipid nanoparticle (LNP) composed of specific lipids. The LNP protects the mRNA and delivers it safely into the cell, where it is released.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $220.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2022
Details:
Evonik to supply commercial quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam is a novel drug, discovered at Cassava Sciences, that targets both neuroinflammation and neurodegeneration.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cassava Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021
Details:
Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the partnership between Evonik and the Comirnaty, vaccine manufacturer BioNTech.
Lead Product(s): Tozinameran
Therapeutic Area: Infections and Infectious Diseases Product Name: Comirnaty
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 11, 2021